title: Prognostic value of miR-106b expression in breast cancer patients.
abstract: BACKGROUND
  The aim of the present study was to evaluate whether the level of expression of tissue or plasma miR-106b can be used to predict clinical outcomes in breast cancer patients.
  
  
  METHODS
  Both tissue and plasma samples were collected and analyzed from 173 patients with primary breast cancer and a set of 50 women with fibroadenoma. The relative expression levels of miR-106b were determined using real-time quantitative reverse transcription polymerase chain reaction and in situ hybridization.
  
  
  RESULTS
  The levels of miR-106b were upregulated in both tissue and plasma samples from breast cancer patients. The expression levels showed a linear correlation (rs = 0.748, P < 0.001) and were significantly correlated with tumor size, Ki67 expression, and lymph node metastasis (all P < 0.05). Patients with high miR-106b expression levels tended to have shorter disease-free survival times and overall survival times (P < 0.001). In a Cox regression model, high-level tissue and plasma miR-106b expression were unfavorable prognostic factors, and receiver-operating characteristic analysis revealed that the tissue and plasma miR-106b levels provided considerable diagnostic accuracy, yielding an area under the ROC curve of 0.785 and 0.856, respectively.
  
  
  CONCLUSIONS
  MiR-106b was found to be associated with a high risk of recurrence of breast cancer, and miR-106b is a putative plasma marker for risk assessment in patients with breast cancer.
authors.affiliation: Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China; Department of Biotechnology, School of Life Science, Sun Yat-Sen University, Guangzhou, People's Republic of China.
authors.forename: Ruohui
authors.initials: R
authors.lastname: Zheng
authors.affiliation: Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
authors.forename: Lingxiao
authors.initials: L
authors.lastname: Pan
authors.affiliation: Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
authors.forename: Jin
authors.initials: J
authors.lastname: Gao
authors.affiliation: Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
authors.forename: Xigang
authors.initials: X
authors.lastname: Ye
authors.affiliation: Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
authors.forename: Lun
authors.initials: L
authors.lastname: Chen
authors.affiliation: Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China.
authors.forename: Xiaoshen
authors.initials: X
authors.lastname: Zhang
authors.affiliation: Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China. Electronic address: wayetom@163.com.
authors.forename: Wei
authors.initials: W
authors.lastname: Tang
authors.affiliation: Department of Breast Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People's Republic of China. Electronic address: wenbo_zheng@163.com.
authors.forename: Wenbo
authors.initials: W
authors.lastname: Zheng
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D001940:Breast / Q000473:pathology; D001943:Breast Neoplasms / Q000097:blood* / Q000401:mortality / Q000473:pathology; D016022:Case-Control Studies; D002681:China / Q000453:epidemiology; D005260:Female; D006801:Humans; D035683:MicroRNAs / Q000097:blood*; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000097:blood*; D011379:Prognosis
chemical_list: D014408:Biomarkers, Tumor; C542541:MIRN106 microRNA, human; D035683:MicroRNAs
keywords: Biomarker; Breast cancer; MiR-106b; Plasma; Prognostic